Estradiol/Norgestimate Shortage: What Providers and Prescribers Need to Know in 2026

Patients prescribed Estradiol/Norgestimate (Prefest) are increasingly reporting difficulty filling their prescriptions in 2026. As a prescriber, understanding the supply landscape, your therapeutic alternatives, and how to counsel patients proactively will help you manage this situation effectively. This clinical resource covers current availability status, switching guidance, and how to help patients navigate access challenges.

Current Availability Status

As of 2026, Prefest (Estradiol/Norgestimate, manufactured by Teva Pharmaceuticals) is not listed on the FDA Drug Shortages database as an active shortage. However, prescribers should be aware that real-world access challenges exist:

• Prefest is a brand-only product with no FDA-approved generic equivalent and limited routine stocking at many retail pharmacies.
• The broader HRT supply chain has been under significant pressure since late 2025 due to sharply increased demand following FDA label changes for menopausal hormone therapy products.
• The acute shortage of transdermal estradiol patches has redirected patients toward oral HRT products, increasing demand for products like Prefest.
• Patients in rural areas or those relying on smaller independent pharmacies may experience more significant access challenges.

Pharmacological Context: What Makes Prefest Unique

Prefest uses a Constant Estrogen/Intermittent Progestogen (CIOP) regimen: 1 mg estradiol for 3 days followed by 1 mg estradiol + 0.09 mg norgestimate for 3 days, cycling continuously. This intermittent progestin approach was designed to provide endometrial protection while potentially reducing continuous progestin exposure. Key pharmacological points:

• Norgestimate is a third-generation progestin with low androgenicity and minimal impact on lipid profiles, which may be relevant for patients with cardiovascular risk factors.
• The active metabolites of norgestimate (17-deacetylnorgestimate and norelgestromin) do not bind to SHBG, unlike some other progestins.
• Prefest is indicated only for women with an intact uterus. The progestin component is essential to protect against endometrial hyperplasia and cancer from unopposed estrogen.

Therapeutic Alternatives and Switching Guidance

When Prefest is unavailable, the following alternatives provide equivalent therapeutic effect for women with an intact uterus requiring combined HRT:

• Estradiol/Norethindrone Acetate (Activella, generic): Continuous combined oral tablet. Available as 1 mg/0.5 mg and 0.5 mg/0.1 mg. Generic available; widely stocked. Most clinically similar switch from Prefest as both use bioidentical estradiol.
• Conjugated Estrogens/MPA (Prempro, generic): Continuous combined oral tablet. Uses conjugated equine estrogens rather than bioidentical estradiol. Available as 0.3/1.5 mg, 0.45/1.5 mg, 0.625/2.5 mg, or 0.625/5 mg. Widely available; generic options exist.
• Estradiol + Micronized Progesterone (oral or vaginal): Separate prescriptions allow dose adjustment of each component. Micronized progesterone (Prometrium) is bioidentical; some patients and providers prefer it for this reason. Cyclic regimen: progesterone 200 mg daily for 12–14 days per cycle; continuous: 100 mg nightly.
• Transdermal Combination Patches (CombiPatch, Climara Pro): Note that transdermal estradiol patches are currently experiencing active supply challenges in 2026. Verify availability before switching patients to this modality.
• Conjugated Estrogens/Bazedoxifene (Duavee): TSEC approach; appropriate for women intolerant to progestins. Brand-only; more expensive; may require prior authorization. Not FDA-approved for osteoporosis prevention in this combination.

Clinical Considerations When Switching

When switching a patient from Prefest's intermittent progestogen regimen to a continuous combined product:

• Counsel patients to expect potential breakthrough bleeding or spotting for 3–6 months as the endometrium adjusts to continuous combined therapy.
• Consider endometrial evaluation if irregular bleeding persists beyond 6 months or is heavy.
• When switching to a different progestin class, monitor for changes in mood, bloating, or breast tenderness, as progestin tolerability varies between patients.
• For patients with cardiovascular risk factors, note that oral estrogen carries a modestly higher VTE risk than transdermal delivery due to first-pass hepatic metabolism effects on clotting factors.

Boxed Warning Considerations

Prefest carries boxed warnings for cardiovascular disorders, breast cancer, endometrial cancer, and probable dementia — based largely on WHI and WHIMS data from conjugated estrogens + MPA. It is important to note that:

• The WHI data was primarily from a single regimen (conjugated estrogens + MPA) in women aged 50–79, many of whom started HRT years after menopause. Results may not directly apply to younger recently menopausal women starting therapy close to menopause onset.
• The FDA's late-2025 label updates removed or softened warnings for certain HRT formulations — particularly transdermal products. Oral combination products like Prefest retain their existing boxed warning language as of the 2024 label revision.
• Individual patient risk assessment (personal and family history of breast cancer, cardiovascular disease, VTE, and dementia) remains essential when prescribing and maintaining any combined HRT.

Helping Patients Find Prefest When It Is Available

When patients prefer to continue Prefest and you want to help them access it, consider recommending medfinder for providers. medfinder calls pharmacies near the patient to check real-time stock and texts them results — saving time for both patients and your office staff who might otherwise field calls about where to find the medication. Encouraging patients to refill 10–14 days early and to consider mail-order for 90-day supplies can also significantly reduce access disruptions.

Patient Counseling Points

Key messages to give patients experiencing Prefest access issues:

• Do not stop HRT abruptly. Symptoms (hot flashes, sleep disruption, vaginal atrophy) will return, often acutely.
• Contact the office before running out so a bridge prescription can be arranged if needed.
• There are effective, FDA-approved alternatives that provide the same endometrial protection and symptom relief.
• Use medfinder or call independent pharmacies to check real-time availability before assuming the medication is unavailable everywhere.

The Bottom Line

While Estradiol/Norgestimate (Prefest) is not in an official national shortage, real-world access issues are frequent in 2026. Proactive communication with patients about refill timing, accessible alternatives, and available resources like medfinder can significantly reduce disruption to HRT therapy. For more practical strategies on helping your patients find Prefest, see our provider's guide to helping patients find Estradiol/Norgestimate in stock.